Mar 2024 ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie.
Feb 2024 ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)
Jan 2024 ProLynx announces a publication proposing that a long-acting prodrug SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors
Oct 2022 ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic
Sept 2022 ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director
July 2020 ProLynx announces SBIR grant award to develop long-acting parathyroid hormone for hypo-parathyroidism
April 2020 ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38) with the PARP inhibitor Rubraca® (rucaparib) at the National Cancer Institute
September 2019 ProLynx announces publication and initiation of patient recruitment for a trial of once-monthly treatment of diabetes in cats
May 2019 ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
August 2018 ProLynx and Daiichi Sanko announce the development of technology for the half-life extension of small molecules in the eye
April 2018 ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
April 2018 ProLynx extends lead in half-life extension platform technology-- Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
Sept 2017 ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
June 2017 ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
June 2017 ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
May 2017 ProLynx issued US patent for cleavable linker technology on hydrogels
June 2015 ProLynx announces active IND of a novel ultra-long acting PEG-SN-38 conjugate to treat solid tumors
February 2015 ProLynx issued key patent for using releasable linkers on insoluble carriers
November 2014 ProLynx awarded NSF Phase II grant for hydrogel platform research and development
August 2014 ProLynx enters funded evaluation agreement with GlaxoSmithKline Research & Development Limited (GSK)
June 2014 ProLynx granted US Patent 8,754,190 covering clinical candidate PEG-SN38
May 2014 ProLynx & RxGen publish data on ocular delivery platform at ARVO 2014 Annual Meeting
April 2014 US Patent 8,703,907 on controlled release from dendrimers
March 2014 Publication in JMedChem relating to PEG-SN-38 conjugates with ultra-long half life, low Cmax, and low glucuronide formation; Japanese partner advances toward Phase I trials.
March 2014 US Patent 8,680,315 on Beta-Eliminative Linkers
September 2012 Bayer Healthcare CoLaborator
April 2012 BioCentury